An interventional study of airtraq video laryngoscope in Obesity, Morbid, Intubation; Difficult or Failed and Video Laryngoscope, sponsored by Kocaeli University. Recruiting at 2 sites in Turkey. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-28.
Sponsored by Kocaeli University · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Obesity, Morbid with a site in Turkey — 8 open to participants now, 8 under way, 1 of them phase 3. Obesity, Morbid · Turkey.
Among the 70 studies in Obesity, Morbid with a site in Turkey, this one is the 13th largest by planned enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2024, is one of 33 with no phase, and was the 46th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →8 of the 70 studies in Obesity, Morbid with a site in Turkey are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Turkey, Germany, Spain
Ages 2+
Harran University · Sites in Turkey
Ages 18–65 · Healthy volunteers
Başakşehir Çam & Sakura City Hospital · Sites in Turkey
Ages 18–65
Gazi University · Sites in Turkey
Ages 18+
Toros University · Sites in Turkey
Ages 19–50
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 66 across the 38 interventional studies, 68 across the 32 observational. Of the 52 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 70 have an industry lead sponsor. The 10 most frequent:
Kocaeli University is the lead sponsor of 215 studies on the registry; 39 are open to participants now.
Kocaeli University has 2 studies filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity, Morbid with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220772Phase 3Regeneron PharmaceuticalsA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | 2027-06-18 |
| NCT07643376Toros UniversityEvaluation of Metabolic Parameters, Intestinal Permeability and Gastrointestinal Symptoms After Bariatric Surgery in Body Weight Management | 2027-01-01 |
| NCT07668765Gazi UniversityGLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | 2027-04 |
| NCT05927519Kocaeli UniversityComparison of Airtraq in Class 2-3 Obese and Nonobese Men During Intubation: a Prospective Randomized Clinical Study | 2027-10-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 70 studies in Obesity, Morbid with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Morbid obesity is a growing disease. Intubations of these patients mostly difficult. Video laryngoscopes have to be used during the intubation of these patients. The intubation of men is more complicated and difficult than obese women. There were no trials compared to the new video laryngoscopes in morbidly obese men. Patients will be divided into two groups; non-obese and klas 2-3 obese. Airtraq will be used for their intubation. The time for intubation will be the primary aim of this prospective randomized study. The insertion time, perioperative hemodynamic variables, and postoperative complications will also be recorded.
Morbid obesity is a growing disease. Intubations of these patients mostly difficult. Video laryngoscopes have to be used during the intubation of these patients. The intubation of men is more complicated and difficult than obese women. There were no trials compared to the new video laryngoscopes in morbidly obese men. Patients will be divided into two groups; non-obese and klas 2-3 obese. Airtraq will be used for their intubation. The time for intubation will be the primary aim of this prospective randomized study. The insertion time, need of optimization menuvers, perioperative hemodynamic variables, and postoperative complications will also be recorded.
Inclusion Criteria:> 18 age men gender elective operation requring intuabtion -
Exclusion Criteria:\<18 age women emergency operation
-
Class 2 (bmı \>35) weight kg/height m2 and class 3 (bmı\>40) obese men
Device: airtraq video laryngoscope
bmı\<30 weight kg/ height m2 men
Device: airtraq video laryngoscope
airtraq video laryngoscope will be used for intubations
intubation time
the intubation time will be recorded beginning the insertion of the Airtraq through the mouth still the endotracheal tube seen passing through the vocal cords
Time frame: 50 seconds
insertion time
inserting the Airtraq through the mouth till the optimal glottic vizualization occurred
Time frame: 20 seconds
peroperative hemodynamic variable
heart rate
Time frame: 4 hours
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Oct 2027, 35 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 35 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.